Partnering for New Findings
Clinical trials are a major step to translate pharmacological potential into clinical safety & efficacy
- =NeuroAiD™, our first product for post-stroke recovery, was commercialized for the first time in Singapore in 2006.
- =It is today available in over 35 countries in South-East Asia, Europe, Africa and Middle-East.
We bring together the world’s top scientists’ in molecular biology, pharmacology and brain injuries to conduct our research and development on the principles of Evidence-Based Medicine.
The research on NeuroAiD™ is still very active
The research on NeuroAiD™ is still very active in post-stroke recover but also in new indications for NeuroAiD™ such as traumatic brain injuries and neurodegenerative diseases (i.e. Alzheimer disease). On average, 4 to 5 papers are published each year by independent researchers, and communicated in international conferences on stroke.
If you represent an institution interested in academic partnerships for clinical trial in:
- =Post Stroke Recovery
- =Neurosurgical Diseases
- =Neurodegenerative Diseases
Please contact us at [email protected]
We will be pleased to have you and your team extending the knowledge of our innovative and promising products.
This form will be sent directly to [email protected] for Research Opportunities.